The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.
 
Michal Kwiatek
No Relationships to Disclose
 
Carmelo Carlo-Stella
Honoraria - AstraZeneca; Celgene; Gilead Sciences; Incyte; Janssen Oncology; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - ADC Therapeutics; Celgene/Bristol-Myers Squibb; Karyopharm Therapeutics; Merck Sharp & Dohme; Novartis; Roche; Sanofi; Scenic Biotech
 
Andrzej Urban
Employment - ADC Therapeutics
Stock and Other Ownership Interests - ADC Therapeutics
 
Andrew Niewiarowski
Employment - ADC Therapeutics
Stock and Other Ownership Interests - ADC Therapeutics
 
Luqiang Wang
Employment - ADC Therapeutics
Stock and Other Ownership Interests - ADC Therapeutics
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Caribou Biosciences; crispr therapeutics; Gamida Cell; Genentech; Genmab; Incyte; Kite/Gilead; MorphoSys; Myeloid Therapeutics; Novartis; Omeros; Puma Biotechnology (I); Sanofi; Seagen; Verastem
Speakers' Bureau - ADC Therapeutics; AstraZeneca; BeiGene; Genzyme; Kite/Gilead
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda